Clik here to view.
2011 BIO International Convention Super Sessions
2011 BIO International Convention Super Sessions Focus on State of the Industry C-Level speakers lead broad conversations on global biotech, industry forecast, and key trends WASHINGTON, D.C. (March 2,...
View ArticleClik here to view.
How to Survive the Patent Cliff: Eli Lilly’s CEO at the BIO CEO & Investor...
Like a number of companies, Eli Lilly is confronting a wave of patent expirations called the patent cliff. The company lost U.S. patent protection on the anti-psychotic Zyprexa in the fall of 2011 and...
View ArticleJ.P. Morgan Turns All Eyes toward Biotech
BioWorld’s Peter Winter reports that the mood is upbeat at today’s kickoff of the 33rd annual J.P. Morgan Healthcare Conference in San Francisco (check out the story here, subscription required)....
View ArticleJohn Lechleiter Forbes Op-Ed: Debunking the Five Big Myths About ‘Big Pharma’
This week, Eli Lilly and Company President, Chairman and CEO John Lechleiter refutes five big myths about big pharma in this Forbes opinion piece. He points to these five biggest industry myths as...
View Article
